FDA Approves Drug Targeting Johns Hopkins-Discovered Brain Cancer Gene Mutation

La FDA aprueba un fármaco dirigido a una mutación genética del cáncer cerebral descubierta en Johns Hopkins

Se ha desarrollado un nuevo fármaco para el tratamiento de un tipo de cáncer cerebral, llamado glioma de bajo grado con mutación IDH. aprobado El 6 de agosto, la Administración de Alimentos y Medicamentos de Estados Unidos (FDA) aprobó el uso de este medicamento. El nuevo y prometedor fármaco se deriva de un descubrimiento genético realizado en 2008 en la Centro Oncológico Johns Hopkins Kimmel.

APRENDE MÁS

VER TODAS LAS NOTICIAS

Mensajes recientes

New Technology: MRI-guided Focused Ultrasound for Prostate Cancer Advances in Breast Cancer Treatment: Insights from Medical Oncologist Jenni Sheng Early Immunotherapy Shows Promising Results in Advanced Basal Cell Carcinoma New NIH-Funded Johns Hopkins Medicine Study Finds High-Risk Individuals Who Have Mild Dilatation of the Pancreatic Duct Have Increased Risk for Pancreatic Cancer Lung Cancer Symptoms Doctors Say Women Should Never Ignore and the Screening Most Skip Targeted Radiation During Surgery Reduces Pancreatic Cancer Recurrence Colorectal Cancer Is Becoming More Common In Young People. Here Are The Signs. Johns Hopkins-Led Study Finds Drugs Approved for Treating Pain Also Reduce Bone Cancer Growth DNA Shed by Colon Cancers May Help Oncologists Personalize Postsurgical Treatment